https://www.selleckchem.com/products/U0126.html
4 mSv (thorax) per fraction for a risk estimate of 0.004% (brain), 0.01% (HN), 0.1% (pelvis), and 0.2% (thorax). Calculated ESD were compatible with existing data. CONCLUSIONS Dose calculation models for CyberKnife IGRT kV beams were implemented in a clinical treatment planning system and validated in water and heterogeneous phantoms. We determined the effective dose and the related risk estimate resulting from CyberKnife IGRT protocols for brain, head and neck, thorax, and pelvis cases. The effective doses calculated for CyberKnife
Like
Comment
Share
